会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Document processing device
    • 文件处理装置
    • US6072474A
    • 2000-06-06
    • US674108
    • 1996-07-03
    • Takeshi MorimuraTadashi WatanabeYuichi Fukui
    • Takeshi MorimuraTadashi WatanabeYuichi Fukui
    • G06F3/023G06F3/0488G06F3/0489G09G5/00
    • G06F3/04892G06F3/0488
    • When a user touches a tablet with a pen, a coordinate pointed with a nib of a pen and a tool force on this coordinate are detected, and a cursor is displayed at a position corresponding to the coordinate in a display device. Furthermore, the shape, color and size, etc., of the cursor can be varied according to a change in coordinate, tool force. This permits the user to recognize a level of the tool force which he actually applies at a glance. Additionally, an operational mode is switched according to an amount of change in detected coordinate and the tool force. As a result, the user is permitted to control an operational mode of the document processing device with ease only by a pen operation, thereby improving an operability.
    • 当用户用笔触摸平板电脑时,检测到与笔的笔尖和该坐标上的工具力指向的坐标,并且在与显示装置中的坐标相对应的位置处显示光标。 此外,光标的形状,颜色和尺寸等可以根据坐标,刀具力的变化而变化。 这使得用户能够一目了然地识别他实际应用的工具力的水平。 此外,根据检测到的坐标和工具力的变化量来切换操作模式。 结果,允许用户仅通过笔操作容易地控制文档处理设备的操作模式,从而提高可操作性。
    • 4. 发明授权
    • Rhodanine derivatives, process for their preparation, and aldose
reductase inhibitor containing the rhodanine derivatives as active
ingredients
    • US4791126A
    • 1988-12-13
    • US96808
    • 1987-09-10
    • Tadao TanouchiMasanori KawamuraAkio AjimaTetsuya MohriMasaki HayashiHiroshi TerashimaFumio HirataTakeshi Morimura
    • Tadao TanouchiMasanori KawamuraAkio AjimaTetsuya MohriMasaki HayashiHiroshi TerashimaFumio HirataTakeshi Morimura
    • C07D277/20C07D277/36A61K31/425
    • C07D277/20
    • The rhodanine derivatives of the general formula: ##STR1## [wherein (I) R.sup.1 and R.sup.2 are taken together to represent a tetramethylene or pentamethylene group; (II) R.sup.1 represents a hydrogen atom, and R.sup.2 represents (1) a cycloalkyl or cycloalkenyl group of 4-7 carbon atoms which is unsubstituted or substituted by at least one alkyl group of 1-4 carbon atoms, (2) an anthryl or naphthyl group, (3) a phenyl group which is unsubstituted or substituted by at least one of (a) halogen atom, (b) trifluoromethyl group, (c) hydroxyl group, (d) nitro group, (e) carboxyl group, (f) amino group which may be substituted by alkyl group(s) of 1-4 carbon atoms, (g) alkyl, alkoxy or alkylthio group of 1-5 carbon atoms, (h) phenyl group, (i) heterocyclic group containing at least one of nitrogen, oxygen and sulfur atoms which is unsubstituted or substituted by at least one of the above-described substituents (a) to (h), and (j) alkyl group of 1-4 carbon atoms which is substituted by at least one of the above-described substituents (c), (h) and (i), (4) a heterocyclic group containing at least one of nitrogen, oxygen and sulfur atoms which is unsubstituted or substituted by at least one of oxo group and the above-described substituents (a) to (h) and (j), or (5) a ##STR2## group (wherein R.sup.4 represents a hydrogen atom, a halogen atom, phenyl group or an alkyl group of 1-5 carbon atoms; and R.sup.5 represents a hydrogen atom, a phenyl group or an alkyl group of 1-5 carbon atoms) or ##STR3## group; or (III) R.sup.1 and R.sup.2, which may be the same or different with each other, each represents a phenyl group which is unsubstituted or substituted by at least one of the above-described substituents (a) to (j); and R.sup.3 represents a hydrogen atom, an alkyl group of 1-12 carbon atoms, an aralkyl group of 7-13 carbon atoms, a cycloalkyl or cycloalkenyl group of 4-7 carbon atoms which is unsubstituted or substituted by at least one alkyl group of 1-4 carbon atoms, or a phenyl group which is unsubstituted or substituted by at least one of the above-described substituents (a) to (j)] and, when R.sup.3 represents hydrogen atom, non-toxic salts of the acids possess a strong inhibitory activity on aldose reductase, and are useful for the prevention and treatment of nerve disturbances such as neuralgia, retinopathy, diabetic cataract and renal disturbances such as tubular nephropathy.